StockWatch
·

Supriya Lifescience Ltd Q2 FY27 Results

SUPRIYAQ2 FY27 Results
Filing
Result:Poor· Market: Crashed#Margin squeeze#Base effect

Outlook: Cautiously Optimistic · Guidance: Cut

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue206.308.7%3.2%
Total Income208.598.4%3.0%
Expenditure170.8112.7%27.2%
PBT37.787.4%44.7%
Net Profit29.2521.7%42.0%
OPM22.01%3.00pp14.34pp
NPM14.02%1.52pp10.88pp
EPS3.6321.4%42.1%
View full financials

Core revenue growth stalled at +3.2% YoY while OPM collapsed to 22% from 36.3% (and missed management's own 32-35% FY27 guidance), driving a fully operational 42% PAT decline with no one-off offset, which caps this as a weak quarter despite a QoQ bounce off a soft Q1 base.

SUPRIYA LIFESCIENCE LTD · Q2 FY27 · THE VERDICT

₹1,000 Crore target now in structural jeopardy — margin collapse unforecasted

Q2 delivered 3.2% YoY revenue growth and −42% PAT decline, with EBITDA margins crashing 13 percentage points to 22%. Management's claim that the LATAM regulatory shock was post-Q1 raises credibility questions; so does the H2 guidance, which now requires 21% QoQ growth to hit the ₹1,000 Cr target.

13 Nov 2026 · 6 min read
Q2 Revenue

₹206 Cr

+3.2% YoY, +8.7% QoQ

Q2 PAT

₹29 Cr

−42% YoY, margin 14%

Q2 EBITDA

₹45 Cr

Margin 22% (was 30%+)

H1 FY27 run-rate

₹396 Cr

₹1,000 Cr target needs ₹604 Cr H2

The quarter opened with a paradox. Revenue grew at low single digits (3.2% YoY), yet EBITDA margins collapsed 13 percentage points to 22%. Reported PAT fell 42% despite a slight QoQ bump. This was not a case of one-time losses; it was organic margin compression driven by three uncontrolled forces: a regulatory shock in LATAM, a heavy ramp-up cost at the Ambernath facility, and raw material inflation. The core tension is this: management guided to 32–35% EBITDA margins only 48 days earlier (in the Q1 FY27 call), and now revised down to 23–25%. The claim that the LATAM regulatory change was post-call and thus unforecasted is difficult to credit, given that 80% of Supriya's revenue is export-driven.

What the quarter actually was

Management framed the quarter as a 'temporary' margin hit driven by three discrete factors: Ambernath facility ramp-up (6 percentage points of margin drag), LATAM regulatory reclassification (3 percentage points), and raw material inflation (3 percentage points). This arithmetic adds to 12 percentage points — yet the actual EBITDA margin fell 13 percentage points. The missing point reflects an unspoken headwind: product mix shift. As LATAM sales stalled (customers blocked by import permits), Supriya shifted sales to semi-regulated markets with lower pricing power, compressing margins further. That margin recovery depends on three simultaneous events: LATAM permits clearing (4–5 month lag from filing), Ambernath EU regulatory audit completing (this month), and new product launches in regulated markets gaining traction. None of these is guaranteed this fiscal year.

Management's claims vs. what the numbers support

LATAM regulatory impact is 'temporary mid-term', not structural

What the numbers show

3–4 countries reclassified products as controlled; import permits 4–5 month lag; ₹25 Cr (~12% of Q2 revenue) stalled

Verdict

Overstated — regulatory reclassification often becomes permanent

Ambernath facility will drive significant revenue and margin uplift

What the numbers show

Facility designed for ₹450–500 Cr capacity; breakeven at ₹160–200 Cr revenue, 1.5 year timeline; ₹60 Cr annual OpEx drag until breakeven

Verdict

Contradicted — facility is pre-revenue until EU audit clears and regulatory approvals received

Confident in maintaining ₹1,000 Cr FY27 revenue guidance

What the numbers show

H1 at ₹396 Cr; H2 needs ₹604 Cr (~21% QoQ growth) amid LATAM disruption and Ambernath pre-revenue ramp

Verdict

Overstated — H2 acceleration is improbable given the headwinds

Margins compressed by exactly 3 discrete factors (Ambernath 6%, LATAM 3%, raw materials 3%)

What the numbers show

Only 12% of ~13% margin gap explained; product mix shift to lower-margin semi-regulated markets accounts for residual 1–2 points

Verdict

Partial — management omitted the mix effect

What changed on this call

  • EBITDA margin guidance cut from 32–35% to 23–25% for FY27

  • LATAM revenue delayed 4–5 months due to import permit reclassification

  • Product mix shifted to semi-regulated markets (lower margins)

  • Ambernath timeline extended: EU audit imminent, regulatory approvals 12+ months beyond

  • CMO aesthetic inhalation contract signature 'imminent' (no concrete timeline)

The bull-bear ledger

Why bulls are holding
  • 74% of revenue from fully backward-integrated products — structural cost advantage

  • Ambernath facility designed for ₹450–500 Cr capacity; genuine long-term growth driver

  • CMO aesthetic inhalation contract (large, multi-country) close to signature

  • New product launches (ADHD, cardiovascular, aesthetic) in pipeline with approvals coming

Why bears are selling
  • Reported PAT −42% YoY, EBITDA margin collapsed 13 pp to 22%

  • Margin guidance miss (32–35% → 23–25% in 48 days) destroys management credibility

  • H2 FY27 requires 21% QoQ growth (vs. 8.7% in Q2) on contingencies not in management's control

  • LATAM revenue (₹25 Cr, 12% of total) stalled; recovery unlikely within FY27

  • Ambernath ₹60 Cr annual OpEx drag persists until ₹160–200 Cr breakeven (1.5 years)

How the street is positioned

The stock closed at ₹644.45 (as of 2026-11-12), down 40.6% from its all-time high of ₹1,085. It is trading well below all three key moving averages: SMA20 ₹803, SMA50 ₹865, SMA200 ₹785. RSI stands at 25.7, deep in oversold territory — the kind of technical setup that typically precedes a relief bounce. Yet the market is NOT catching the dip. FII holdings have declined from 7.19% (Q4 FY25) to 6.19% (Q1 FY27), a trim of 100 basis points — suggesting institutional skepticism rather than panic-buying. Volume is increasing, which is notable; it often indicates either conviction selling or a final washout before reversal. DII holdings are steady at 5.3%, and promoter holding is locked at 68.3%.

What this tells us: The 40% drawdown has not attracted value-buying; instead, informed investors (FII) are slowly trimming, even as technicals scream oversold. This suggests the market has genuinely repriced the ₹1,000 Cr FY27 target and margin recovery thesis as lower-probability events. The stock is not cheap — it is fairly valued for execution risk.

Ranked risks

The risks that matter most to a holder, ranked by severity

Regulatory (LATAM) — product reclassification permanent, not temporary

High

3–4 countries reclassified high-margin products as controlled substances. If reclassification becomes structural or permits take 6+ months, ₹25 Cr annual revenue (~12% of total) is permanently lost and margins remain under pressure.

Operational (Ambernath) — facility ramp-up takes longer than 1.5 years

High

EU audit imminent, but regulatory approvals typically require 12–18 months beyond. ₹60 Cr annual OpEx drag persists until ₹160–200 Cr breakeven. Each quarter of delay costs ₹15 Cr in margin drag.

Execution (H2 FY27 acceleration) — multiple contingencies must align

High

₹1,000 Cr target requires ₹604 Cr in H2 (21% QoQ growth). Contingent on LATAM permits, Ambernath EU approval, and new product scale. If any one slips, FY27 target misses; if two slip, stock falls another 20–30%.

Cost inflation (raw materials & solvents) — pass-through lags price hikes

Medium

Solvent prices driven by crude derivatives and geopolitical tensions. Backward integration gives a buffer, but contract structures typically allow 2–3 quarter pass-through lag. Customers pushing back on price increases; margin recovery delayed.

The debate

What to watch next

The 3 catalysts that resolve the debate
  • 1 · Ambernath EU regulatory audit (November 2026)

    This month's audit determines the timeline for EU product approvals and registrations. If audit clears as promised, regulatory approvals could come by mid-2027. If delayed, the 1.5-year timeline extends further.

  • 2 · LATAM import permit recovery (Q4 FY27 earliest)

    4–5 month lag from filing means recovery unlikely until December at earliest. If customers' permits don't arrive by Q4 FY27, ₹25 Cr revenue slips to Q1 FY28, and ₹1,000 Cr FY27 definitely misses.

  • 3 · H2 FY27 revenue run-rate (Q3 FY27 earnings call)

    Next quarter will confirm whether the company is tracking to ₹604 Cr H2 total (~₹312 Cr Q3–Q4 average). If Q3 comes in below ₹290 Cr, the ₹1,000 Cr target is mathematically off the table.

The number to track

From here, watch the EBITDA margin. Q2 was 22%; guidance is 23–25% for FY27. If Q3 comes in at 22% or below, the margin recovery narrative is cracking. If it ticks up to 24–25%, it signals that the worst is priced in and the company is executing its reset. The absolute number is less important than the trend — compression means the bear case is winning; stabilization means the bulls have room to re-own the stock. The honest verdict is this: Supriya has built a structurally attractive business (backward integration, CDMO footprint, new products), but execution timelines have slipped. The ₹1,000 Cr FY27 target is now a stretch goal. The inflection is FY28+.

The quarter was worse than guidance suggested, but not catastrophic. EBITDA margins will recover — Ambernath is real, the CMO opportunity is real, and FY28 is plausible for a return to 28%+ margins. But the road to that recovery is now longer and more contingent than the street expected. The stock has repriced downward by 40%, and FII is not catching the dip, which tells us institutional investors are waiting for concrete proof (not promises) that the turnaround is underway. For holders, this is a test of conviction: do you believe in FY28 margin recovery, or does the guidance miss break your thesis? For new buyers, this is a 'show me' story — wait for Ambernath EU audit to clear and LATAM permit momentum in Q3 guidance. The company is no longer expensive. It is now fairly valued for execution risk.

Informational and educational content only. Not investment advice.